Patient characteristics, treatment options, the dual biological function of IL-10, and the variation in mutant alleles frequencies between different populations and ethnic groups should all be responsible for the inconsistency in the relationship between IL-10 SNPs and DLBCL risk and outcome. The gene discussed is IL10; the disease is diffuse large B-cell lymphoma.